- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05645211
O eixo AgRP e GH/IGF-1 em crianças
Peptídeo relacionado a Agouti (AgRP) e o eixo GH/IGF-1 em crianças
Recent data support the existence of a GH-Agouti-related peptide (AgRP) axis. The neuropeptide AgRP promotes food intake and has important effects on energy homeostasis. Recent evidence suggest that GH stimulates AgRP and AgRP may mediate some of GH's important nutritional and metabolic effects. main goals of this project are to characterize, for the first time, plasma levels of AgRP in children and to determine how these relate to GH and IGF-1 levels, age, body composition, clinical and other endocrine parameters. To accomplish this, we will conduct two studies, one being a cross-sectional study that will measure AgRP levels in 140 healthy children ages 5-17 and the second being a prospective study that will measure the change in plasma AgRP levels in response to GH treatment in 16 children who receive this as part of their clinical care for GH deficiency or short stature.
Visão geral do estudo
Status
Condições
Descrição detalhada
Protocol 1 This will be a cross-sectional study in 140 healthy children. Participation will include one visit that will take place between 8-9 am and after a fast from midnight the night before.
Procedures at the visit will include:
- Review of medical history
- Anthropometrics measurements: Weight, height, waist and hip circumferences.
- Collection of information from medical record including growth records and physical examination findings including features relevant to pubertal stage in all children and onset of menses in females.
- Assessment of pubertal status and Tanner stage based on physical examination.
- Collection of information on diet, activity level and sleep.
- Blood Sampling: venous blood will be sampled from a peripheral vein for measurement of AgRP, GH, IGF-1, leptin, SOb-R, triglycerides, insulin, glucose, testosterone(males), estradiol(females), DHEAS and cortisol levels. Insulin and glucose levels will be used to assess insulin resistance by HOMA & QUICKI.
Protocol 2 This will be a prospective study in 16 children who will be studied before and at 4 time points (1 week, 2 weeks, 1 month and 2 months) after starting GH treatment as part of their clinical care. This protocol will study subjects Groups 2 and 3. Growth hormone will not be prescribed as part of this study. Children will be treated clinically with GH as prescribed by their Pediatric Endocrinologist for FDA approved indications and according to standard guidelines for dosing for treatment of GH deficiency in children.
Each visit that will take place between 8-9 am and after a fast from midnight the night before.
Procedures at each visit will include:
- Review of medical history
- Anthropometrics measurements: Weight, height, waist and hip circumferences, skinfold thicknesses.
- Collection of information from medical record including growth records and physical examination findings including features relevant to pubertal stage in all children and onset of menses in females. GH dose and compliance will be recorded at follow up visits.
- Collection of information on diet, activity level and sleep.
- Blood Sampling: Venous blood will be sampled at a peripheral vein for:
Baseline (pre-GH treatment): measurement of AgRP, GH, IGF-1, IGFBP-3, leptin, SOb-R, triglycerides, insulin and glucose, testosterone(males), estradiol(females), DHEAS and cortisol levels.
Follow up visits on growth hormone: measurement of AgRP, IGF-1, IGFBP-3, leptin, SOb-R, triglycerides, insulin, glucose and cortisol levels.
Insulin and glucose levels will be used to assess insulin resistance by HOMA & QUICKI.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Pamela Freda
- Número de telefone: 2123052254
- E-mail: puf1@cumc.columbia.edu
Estude backup de contato
- Nome: Rosa Lazarte
- Número de telefone: 2123054921
- E-mail: rl2345@cumc.columbia.edu
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Healthy children: 140 healthy children (70 females and 70 males) between the ages of 5-17 yr. will be studied; 7-8 children per year of this age range will be studied. They will be representative of the diverse racial and ethnic mix of children who receive their medical care at our medical center.Children will be recruited from among the healthy children visiting primary care Pediatricians at our medical center.
GH deficient and idiopathic short stature children: 16 children (8 males, 8 females) between the ages of 5 - 9 yr. who are pre-pubertal and who plan to start GH treatment for isolated GH deficiency or idiopathic short stature. They will be representative of the diverse racial and ethnic mix of our hospital's patient population.
Descrição
Healthy children
Inclusion Criteria:
- Ambulatory male and female children aged 5-17 years
- Normal weight at birth
- Height between the 3rd and 99th percentiles of the mean as per the CDC growth percentiles.
Exclusion Criteria:
- Genetic defects, chronic illnesses.
- Current prescription medication use
- Use of glucocorticoids, thyroid hormone or medications that may affect the GH-IGF-1 axis within 6 months of study entry.
Children with GH deficiency:
Inclusion Criteria:
- Ambulatory male and female children aged 5-9 years who are prepubertal
- Normal weight at birth
- Growth failure
- Peak GH response to 2 GH stimulation tests < 10 ng/ml
- Normal renal and liver function
Exclusion criteria:
- Multiple pituitary hormone deficiencies,
- GH deficiency or poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
- History of diabetes or malignancy
- Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.
Children with idiopathic Short Stature:
Inclusion Criteria:
- Ambulatory male and female children aged 5-9 years who are prepubertal
- Normal weight at birth
- Height >2.25 SD below mean for age
- Peak GH response to 2 stimulation tests >10 ng/ml or normal IGF-1 and IGFBP-3 levels
- No prior supplemental growth hormone exposure
- Normal renal and liver function
Exclusion criteria:
- Poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
- History of diabetes or malignancy
- Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: CROSS_SECTIONAL
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Group 1: Healthy children
140 healthy children (70 females and 70 males) between the ages of 5-17 yr. will be studied; 7-8 children per year of this age range will be studied. They will be representative of the diverse racial and ethnic mix of children who receive their medical care at our medical center. Inclusion Criteria:
Exclusion Criteria:
|
|
Group 2: Children with GH deficiency
16 children (8 males, 8 females) between the ages of 5 - 9 yr. who are pre-pubertal and who plan to start GH treatment for isolated GH deficiency or idiopathic short stature. They will be representative of the diverse racial and ethnic mix of our hospital's patient population. GH deficiency: Inclusion Criteria:
Exclusion criteria:
|
|
Group 3: Children with short stature
Idiopathic Short Stature: Inclusion Criteria:
Exclusion criteria:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Protocol 1: Correlation of Plasma AgRP levels with IGF-1 levels
Prazo: Baseline (cross-sectional at single time point, no intervention)
|
Plasma AgRP levels correlation with IGF-1 levels Protocol 1: Correlation of Plasma AgRP levels with IGF-1 levels |
Baseline (cross-sectional at single time point, no intervention)
|
|
Protocol 2: Change in plasma AgRP levels with GH therapy
Prazo: baseline to 2 months
|
Change in plasma AgRP levels from pre-GH therapy to post-GH therapy |
baseline to 2 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Protocol 1: Correlation of plasma AgRP levels with age
Prazo: Baseline (cross-sectional testing at one time point, no intervention)
|
Correlation of plasma AgRP levels with age |
Baseline (cross-sectional testing at one time point, no intervention)
|
|
Protocol 1: Correlation of plasma AgRP levels with leptin levels
Prazo: Baseline (cross-sectional testing at one time point, no intervention)
|
Correlation of plasma AgRP levels with leptin levels |
Baseline (cross-sectional testing at one time point, no intervention)
|
|
Protocol 1: Correlation of plasma AgRP with percent body fat (determined from skinfold thickness)
Prazo: Baseline (cross-sectional testing at one time point, no intervention)
|
Correlation of plasma AgRP with percent body fat (determined from skinfold thickness) |
Baseline (cross-sectional testing at one time point, no intervention)
|
|
Protocol 2: Change in AgRP levels correlation with change in IGF-1 levels
Prazo: Baseline to 2 months
|
Correlation of change in AgRP levels with change in IGF-1 levels from baseline to 2 months of GH therapy |
Baseline to 2 months
|
|
Protocol 2: Change in AgRP level correlation with pre-treatment leptin levels
Prazo: Baseline to 2 months
|
Correlation of change in AgRP level from baseline to 2 months of GH therapy with pre-treatment leptin levels |
Baseline to 2 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- AAAU4134
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .